<DOC>
	<DOC>NCT02607800</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) and SOF/VEL in adults with chronic HCV infection who have not previously received treatment with direct-acting antiviral therapy.</brief_summary>
	<brief_title>Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Willing and able to provide written informed consent HCV RNA ≥ 10^4 IU/mL at screening Chronic HCV infection (≥ 6 months) HCV treatment naive or treatment experienced with an interferon (IFN)based regimen Use of protocol specified methods of contraception Key Current or prior history of clinically significant illness that may interfere with participation in the study Screening ECG with clinically significant abnormalities Laboratory parameters outside the acceptable range at screening Pregnant or nursing female Chronic liver disease not caused by HCV Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic Hepatitis C Infection</keyword>
</DOC>